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Tripartite motif (TRIM) proteins are novel players in antiviral innate immunity. In this issue of Cell Host &
Microbe, Taylor et al. (2011) discover the mechanism of action of TRIM79a and show that this interferon-
induced protein restricts tick-borne flaviviruses by targeting the viral polymerase for degradation.Viruses of the genus Flavivirus, family
Flaviviridae, are arthropod-borne viruses
that cause a wide spectrum of disease
manifestations ranging from mild fever to
encephalitis and hemorrhagic disease.
Clinically relevant viruses of this genus
are dengue virus, yellow fever virus, West
Nile virus (WNV), and Japanese encepha-
litis virus, all of which are transmitted to
humans by mosquitoes. A second group
within the genus Flavivirus comprises
tick-borne viruses, including tick-borne
encephalitis virus (TBEV), which cause
several thousand cases of encephalitis
across Europe and Asia annually. In addi-
tion, travelers to endemic areas are at
risk of exposure to ticks infected with
these viruses, which therefore pose a
serious global health concern (Gould
and Solomon, 2008).
On the molecular level, flaviviruses are
enveloped viruses with a positive-sense
single-stranded RNA genome encoding
a single open reading frame. Translation
results in a large polyprotein that is
cleaved and gives rise to three structural
(C, M, and E) and seven nonstructural
(NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5) proteins (Figure 1). NS5, the
largest and most conserved flaviviral
protein, is multifunctional: it exhibits
methyltransferase and RNA-dependent
RNA polymerase activities and forms,
together with NS2B and NS3, the viral
replication complex. In addition, NS5 an-
tagonizes the host type I interferon (IFN)
system, partly by inhibiting the JAK-
STAT pathway, thereby suppressing the
transcription of IFN-stimulated genes
(ISGs) (Diamond, 2009).
ISGs, as the name indicates, are in-
duced by IFNs and encode important
host cell factors that mediate antimicro-
bial defense mechanisms. Since their
discovery more than 25 years ago (Knightand Korant, 1979), only a few of the
large number of identified ISGs have
been characterized functionally. Recent
studies have shown that many members
of the tripartite motif (TRIM) protein family
are expressed in response to IFNs and
play crucial roles in antiviral innate immu-
nity (Ozato et al., 2008).
The TRIM protein superfamily com-
prises more than 60 members in humans,
many of which have orthologs in other
species. Structurally, TRIM proteins are
characterized by the RBCC motif, com-
prising a RING-finger domain, one or two
B-boxes, and a coiled-coil domain
(CCD). In most TRIM proteins, the RBCC
motif is followed by a SPRY domain. The
functions of these domains are quite well
understood. The RING domain of many
TRIM proteins confers ubiquitin E3 ligase
activity, and this enzymatic activity has
often been linked to their antiviral function.
While no clear function has been assigned
to the B-box, the CCD and the SPRY
domain have been shown to mediate,
respectively, TRIM oligomerization and
the interaction with other proteins.
TRIM proteins have at least two distinct
modes of antiviral action. Some TRIMs
directly target viral proteins to suppress
or ‘‘restrict’’ virus replication. These
TRIM family members belong to the larger
group of antiviral restriction factors. In
addition, other TRIM proteins have
evolved that target cellular signaling
molecules to modulate signal transduc-
tion pathways leading to the production
of IFNs and proinflammatory cytokines
(McNab et al., 2011). Importantly, the
signal-modulatory function of many
TRIMs is dependent on their ability to
catalyze specific types of polyubiquitin
chains, which do not lead to the proteaso-
mal degradation of the substrate protein,
but instead activate it. TRIM25 andCell Host & Microbe 10, SeTRIM23, for example, have been demon-
strated to positively regulate signal trans-
duction initiated by RIG-I, a key cytosolic
sensor for the detection of viral RNA.
Specifically, TRIM25 interacts with RIG-I
and induces its K63-linked ubiquitination,
thereby enabling RIG-I to initiate down-
stream signaling leading to type I IFN
induction (Gack et al., 2007). TRIM23
modifies NEMO, an essential molecule
downstream of RIG-I and other receptors,
through K27-linked ubiquitination. As
with RIG-I, ubiquitination of NEMO leads
to its activation, thereby triggering IFN-
mediated antiviral immune responses
(reviewed by McNab et al., 2011).
The most famous example of a TRIM
protein that acts as an antiviral restriction
factor is TRIM5a, which restricts the
infection of diverse retroviruses, including
HIV-1. Mechanistically, the SPRY domain
of TRIM5a binds to the viral capsid soon
after virus entry into the host cell, thereby
inducing premature capsid disassembly.
Interestingly, retrovirus restriction by
TRIM5a is species specific. TRIM5a of
rhesus monkey potently restricts HIV-1,
whereas human TRIM5a only modestly
blocks HIV-1 infection (reviewed by Ozato
et al., 2008). In addition, TRIM5a has been
recently shown to activate signaling
pathways leading to NF-kB and AP-1
activation, suggesting that TRIM5a acts
as an innate immune sensor responsible
for detecting retroviral capsids (Pertel
et al., 2011).
Now, Taylor and colleagues (2011) add
TRIM79a to the growing list of antiviral
restriction factors. Remarkably, TRIM79a
specifically restricted tick-borne flavivi-
ruses, but not the mosquito-borne WNV.
Using a yeast two-hybrid screening, the
authors identified TRIM79a as an inter-
action partner of the NS5 protein of Lan-
gat virus (LGTV), a naturally attenuatedptember 15, 2011 ª2011 Elsevier Inc. 175
Figure 1. TRIM79a Targets the Replication Complex of TBEV for Lysosomal Degradation by Binding to the Viral NS5 Protein
Upon infection with tick-borne flaviviruses, translation of the viral RNA genome results in the expression of structural (C, M, E) and nonstructural (NS1-5) proteins.
NS5, the largest viral protein, has multiple functions: (1) viral RNA replication as part of the viral replication complex, (2) IFN suppression by inhibiting the
JAK-STAT pathway, and as shown for some flavivirus members, (3) immune evasion of IFIT proteins (Daffis et al., 2010). Taylor et al. (2011) show that cellular
TRIM79a is induced by type I IFNs and binds to NS5 of TBEV and LGTV. This leads to lysosomal degradation of the viral replication complex.
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TRIM79a is a rodent specific TRIM pro-
tein not expressed in humans, they first
tested the TRIM79a expression levels in
different mouse organs. This revealed
that TRIM79a is broadly expressed, with
particularly high expression levels in
spleen, lymph node, and bone marrow.
Furthermore, IFN-b treatment or virus in-
fection strongly induced TRIM79a gene
expression in murine cells, providing the
first hint that this protein may be involved
in antiviral defense. TRIM79a specifically
interacted with NS5 of LGTV and TBEV,
but not with NS5 of WNV or Japanese
encephalitis virus. Strikingly, ectopic ex-
pression of TRIM79a induced rapid deg-
radation of LGTV NS5 protein.
In the second series of experiments,
the authors asked how TRIM79a caused
NS5 degradation and whether ubiq-
uitination induced by TRIM79a RING
domain played any role. A critical experi-
ment showed that a TRIM79aRING-finger
mutant with mutation of the catalytic ac-
tive site still efficiently induced NS5 deg-
radation. Surprisingly, inhibitors of the
lysosomal pathway but not of the protea-176 Cell Host & Microbe 10, September 15, 2somal pathway prevented NS5 degrada-
tion by TRIM79a, indicating that TRIM79a
induces lysosomal degradation of NS5.
The authors further showed that not
only NS5 but the entire viral replication
complex, NS2B/NS3/NS5, is targeted for
destruction by TRIM79a (Figure 1).
Does NS5 degradation by TRIM79a
impact viral replication? Taylor et al.
(2011) observed a strongly reduced repli-
cation of LGTV in human cells stably ex-
pressing TRIM79a compared to control
cells. This restriction was not due to an
increased IFN production in TRIM79a-ex-
pressing cells (IFN-b protein levels of
these cells were even reduced compared
to control cells). This corroborates that
TRIM79a directly targets the virus rather
than inducing innate immune signaling
pathways leading to IFN production. The
group also addressed the important
question of whether TRIM79a restricts
other flavivirus members. TRIM79a effi-
ciently suppressed TBEV replication;
however, it did not restrict WNV infection.
Finally, the authors examined the impact
of TRIM79a antiviral action for the type I
IFN-mediated host response. For this,011 ª2011 Elsevier Inc.murine macrophage cells in which en-
dogenous TRIM79a was silenced using
small hairpin RNA were infected with
TBEV or LGTV and later stimulated with
IFN-b. TRIM79a-knockdown cells ex-
hibited markedly enhanced viral replica-
tion compared to control cells, indicating
that TRIM79a is required for effective
IFN-b-mediated suppression of virus
replication.
While the findings by Taylor et al. (2011)
expand our knowledge about TRIM-medi-
ated antiviral restriction, the precise
molecular mechanism of how TRIM79a
induces NS5 degradation has yet to be
unveiled. Various questions remain to be
answered, including: how does TRIM79a
access NS5, which is believed to be
shielded by membranes? And how does
TRIM79a target NS5 for lysosomal degra-
dation without being degraded itself?
Furthermore, the study did not address
whether TRIM79a also inhibits other
functions of NS5.
Probably the most intriguing question
is: does the virus fight back? Coevolution
of viruses and their hosts has led to the
development of powerful mechanisms of
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of human, avian, and swine influenza A
viruses has been shown to interact with
human TRIM25 (Gack et al., 2009). This
interaction inhibits TRIM25 multimeriza-
tion and its enzymatic activity, resulting
in the abolished RIG-I ubiquitination and
host antiviral IFN response. Thus, it will
be interesting to investigate whether
NS5 or other proteins of flaviviruses
have acquired the ability of inhibiting
TRIM79a antiviral activity. Finally, as flavi-
viruses are known to adapt to different
host species, it is tempting to speculate
that evasion of TRIM antiviral restriction
factors could determine flavivirus host
adaptation and pathogenicity in the dif-
ferent hosts. Therefore, future studies
determining the interactions of flaviviralproteins with host-encoded antiviral re-
striction factors will not only shed light
on flavivirus host tropism, but may also
unveil therapeutic targets urgently needed
to treat flavivirus infections in humans.
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The HCMV-neutralizing monoclonal antibody MSL-109 failed to prevent HCMV-induced disease in the clinic.
In this issue of Cell Host & Microbe, Manley et al. (2011) found that MSL-109 rapidly induces antibody resis-
tance by a nongenetic mechanism. Their results shed light on how antibodies can interact with their targets
both outside and inside infected cells and virions.MSL-109 is a naturally occurring human
antibody that blocks human cytomegalo-
virus (HCMV) infection of many cell types
by targeting the key virion envelope
protein complex, gH/gL. In all herpesvi-
ruses, gH/gL and another glycoprotein,
gB, form the core fusion machinery that
is essential for virus-cell fusion. The crys-
tal structures of both gB and gH/gL of
HSV and EBV have been solved (Backovic
et al., 2009; Chowdary et al., 2010; Con-
nolly et al., 2011; Heldwein et al., 2006;
Matsuura et al., 2010), and it is clear
from their structures that gB is the fusion
protein, while gH/gL may serve a regula-
tory role in driving fusion, may assist gB
in fusion, or both (Atanasiu et al., 2010;
Connolly et al., 2011; Matsuura et al.,2010). Regardless, both gH/gL and gB,
as key components of the herpesvirus
entry machinery, are targets of therapies
aimed at disrupting entry. Often, anti-
bodies to these proteins can neutralize
virus.
One such antibody is MSL-109.
Because of its properties, this antibody
was chosen for clinical trials as a po-
tential therapy for HCMV disease in
AIDS patients with HCMV-induced reti-
nitis as well as in stem cell transplant
recipients. The failure of MSL-109 in
human clinical trials was a disappointing
outcome, but Manley and colleagues
(Manley et al., 2011) set out to find the
reason for the failure and discover a
surprising outcome.Indeed, Manley et al. (Manley et al.,
2011) provide convincing evidence that
HCMV rapidly develops resistance to the
effects of MSL-109 by a unique nonge-
netic mechanism. Classically, virus resis-
tance to the neutralizing effects of an
antibody develops over time. This occurs
bymutations inoneormoreproteins (often
the target of the antibody) that render
the virus insensitive to the antibody, but
still permit virus replication. However,
this turns out not to be the case for
MSL-109. The first clue was the fact that
resistance developed quite rapidly and
was readily reversible, something that is
not typical of classical resistance.
Amazingly, resistance occurs by up-
take of the antibody during infection andptember 15, 2011 ª2011 Elsevier Inc. 177
